GLP-1 receptor agonists and DPP-4 inhibitors improve metabolic parameters, reduce androgens, increase SHBG, improve menstrual regularity, and enhance fertility in women with PCOS.
26 studiesreviewed showing GLP-1 drugs improve metabolic, hormonal, and reproductive outcomes in PCOS
What the researchers found
GLP-1 RAs and DPP-4 inhibitors showed significant improvements in metabolic parameters (weight, insulin sensitivity), hormonal parameters (reduced androgens, increased SHBG), and reproductive outcomes (improved menstrual regularity, ovulation, and pregnancy) in PCOS.
Why it matters
PCOS has limited treatment options and current therapies often address only individual symptoms. GLP-1 drugs could simultaneously improve metabolic, hormonal, and reproductive outcomes — a comprehensive approach to this multi-faceted condition.
The numbers in context
GLP-1 agonists improved IR and weight in PCOS; some evidence for reproductive benefits.
How the study worked
Narrative review with systematic search of PubMed, MEDLINE, and EMBASE. Identified 854 articles; included 8 animal intervention studies, 14 human intervention studies, 2 case-control studies, 1 observational animal study, and 1 systematic review.
Who was studied
Women with polycystic ovary syndrome across multiple clinical studies
What this study cannot tell us
Narrative review format. Most included studies were small. Heterogeneous study designs and PCOS definitions. Larger randomized controlled trials are needed. Long-term safety of GLP-1 drugs in reproductive-age women needs evaluation.
How to read the evidence
Narrative review synthesizing 26 studies with consistent positive findings. Individual studies were mostly small, and larger RCTs are needed for definitive evidence.
When this study was published
Published in 2021. Interest in GLP-1 drugs for PCOS has grown significantly since, with semaglutide studies underway.
The bigger picture
GLP-1 drugs are increasingly recognized for benefits beyond diabetes and obesity. Their potential in PCOS adds women's reproductive health to the expanding list of conditions where these peptide-based therapies could make a significant impact.
Questions still open
- Would semaglutide, the most potent GLP-1 RA, show even stronger benefits in PCOS than earlier agents?
- Are GLP-1 drugs safe to use during attempts at conception?
- Could GLP-1 therapy replace or complement current first-line PCOS treatments like metformin?
Common questions
What is PCOS?
How might GLP-1 drugs help with fertility in PCOS?
Read the original research
The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.
Therapeutic advances in endocrinology and metabolism, 12, 2042018821989238
Citation
Abdalla, Mohammed Altigani; Deshmukh, Harshal; Atkin, Stephen; Sathyapalan, Thozhukat. (2021). The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.. Therapeutic advances in endocrinology and metabolism, 12, 2042018821989238. https://doi.org/10.1177/2042018821989238